The Cost-Effectiveness of Efgartigimod Alfa (Vy...

By Staff Writer

December 18, 2023

 The Purpose and Pricing of Efgartigimod Alfa Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is pr...
The Value-Based Pricing and Market Access of Valbenazine: A Cost Effective Ev...
Unveiling the Economic Burden of Untreated Mental Illness
The Electronic Clinical Dementia Rating (eCDR): A Promising Tool for Dementia...
Virtual Care: A New Era in Neurology
Transforming Paediatric Care: Virtual Care Modalities Prove Effective and Pro...